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The hypothesis-driven, single-gene analytic approach has
dominated molecular neurobiology research and has been
very successful. In grant submissions, the US National Insti-
tutes of Health demand succinctly defined, closed hypothe-
ses based on expected outcomes. Where does this leave
experiments utilizing high-density microarrays, which do
not fit this mold? The fact that microarray investigators do
not know which genes or pathways will be discovered by
their experiments is precisely the strength of microarrays.
The ability to examine the expression profile of potentially
the entire genome at once, without preconceptions, offers
the possibility of completely novel and unexpected insights
into entities as complex as the nervous system. But before
these insights can be made, the practical problems of experi-
mental design, data analysis, verification, and interpretation
need to be addressed. 
Optimizing experimental models and design 
The full potential of microarrays will be realized only when
the questions that are asked about a system are sophisticated,
rather than seeking simple changes or differences in expres-
sion profiles. We need to avoid experiments that generate
lists of genes, suitable only for archiving and future data
screening. In addition, technical aspects of any experiment
require attention; the speed of tissue removal to prevent RNA
degradation, extraction of high quality RNA, optimal reverse
transcription, amplification, labeling and hybridization with
arrays and the use of quality control measures at each step
are all critical. The suitability of different array formats also
needs to be considered in terms of representation, variability,
and sensitivity. Before considering data analysis and verifica-
tion directly, we will discuss several of the microarray studies
of neurobiological interest that have been completed to date.
In particular, we focus on those aspects of model choice and
experimental design that allow the conclusions of greatest
biological importance to be drawn.
Carefully designed microarray studies have already begun to
offer new forms of biological insight. To illustrate, microar-
rays have been used not only to validate putative drug
targets but also to identify the cellular consequences of drug
treatment and to differentiate target-specific drug effects
from non-specific effects. For example, a comparison has
been made between wild-type yeast treated with FK506, a
putative axon-regeneration-promoting drug [1] that is better
known for its use as an immunosuppressive agent, and
untreated yeast lacking the gene for calcineurin, the drug
target [2]. By identifying genes that were regulated in the
drug-treated yeast lacking the drug’s therapeutic target, the
investigators were able to describe genes representing the
drug’s transcriptional side-effect profile. Yeast studies have
also pioneered the use of arrays to identify cis-acting control
elements that regulate the transcription of many co-regulated
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tial is contingent on sophisticated and rigorous experimental design and data analysis. This article
highlights what is needed to get the most out of microarrays in terms of accurately and effectively
revealing differential gene expression and regulation in the nervous system.genes [3], a phenomenon that may be important in both neu-
ronal development and the response of neurons to injury. 
Another promising neurobiological use of microarrays has
been in studying tumors of the central nervous system: here
arrays have been used not only for diagnosis but also as a
prognostic tool. Pomeroy and colleagues [4] collected a
microarray dataset from 99 embryonic tumor samples asso-
ciated with known diagnoses and patient survival outcomes.
They were able to distinguish the different histopathological
classes of medulloblastoma on the basis of expression pro-
files. In addition, they derived subsets of 21 or fewer genes
whose combined expression levels could classify the medul-
loblastoma samples according to survival versus treatment
failures. There were no known prognostic markers for
medulloblastoma prior to this study.
A variety of experimental models in neuroscience have now
been investigated using microarrays. For example, arrays
have been used to study differences in the expression profiles
of two inbred strains of mice with different levels of suscepti-
bility to seizure [5]. This study found that in a strain of mice
resistant to seizure-induced hippocampal cell death
(C57BL/6) the expression of many more genes was induced in
the hippocampus by seizure than in a strain of mice suscepti-
ble to post-seizure cell death (129SvEv). Other array studies
have examined the effects of diet and aging on the mouse
brain [6,7], and the effects of environmental influences, such
as exposure to an enriched environment [8]. Arrays have also
been used to examine gene-expression changes in models of
Parkinson’s disease [9], in patients with Alzheimer’s disease
[10], and in schizophrenia [11]. Although these studies are so
far purely descriptive or observational, they have uncovered
novel genes or suggested novel mechanisms, the significance
of which now needs to be explored further.
The ability to use microarrays to view changes in expression
induced by null mutations or gene knockouts is also of interest.
A gene-expression study of the pons and cerebellum has
used such a strategy to find genes that are involved in
normal target innervation [12]. In normal mice, pontine
neurons develop a projection that synapses with cerebellar
granule neurons. Diaz and colleagues [12] demonstrated that
in  weaver mutant mice, which lack cerebellar granule
neurons, gene expression in the pons during the develop-
ment of the pontocerebellar projection is altered. Expression
of genes involved in axon outgrowth persists beyond their
normal phase of downregulation after target innervation,
whereas genes involved in synapse formation fail to be
upregulated at the proper time in development. This study is
noteworthy for its careful experimental design and data
analysis. Statistical principles were used to identify regu-
lated genes, and the data were examined using clustering
and linear regression modeling. When microarrays begin to
be used to study the effects of conditional knockout or over-
expression of genes, not only can the compensatory and
downstream effects of the constitutive loss of a gene
throughout development be examined, but global analysis of
the response to perturbations in the levels of single genes in
specific conditions will also be possible [13]. 
Complex tissues and diverse cell populations 
Heterogeneity of the tissue being examined is a major
concern when using arrays to analyze the nervous system.
Zirlinger  et al. [14] have identified region-specific gene
expression within the brains of mice using microarrays. In
addition, they observed that some of the genes they identi-
fied could be grouped into three spatial expression patterns,
each consisting of expression within a different subset of the
amygdaloid subnuclei. Other genes, however, seemed to
exhibit expression patterns that did not conform to neuro-
anatomical subnuclei. Lockhart and Barlow [15] have used
microarrays to compare gene-expression profiles in six
specific regions of the brain (amygdala, cerebellum, cortex,
entorhinal cortex, hippocampus and midbrain) in human
and mouse tissue; they describe 23 genes that are specific to
the cerebellum, giving this region the highest number of
unique genes among the regions they studied. 
Averaging expression levels of an entire region of tissue,
such as the brain or even a specific brain area or nucleus,
will clearly minimize or even conceal large expression
changes that occur in small subpopulations of cells. There
are promising techniques for overcoming this obstacle,
however: laser capture to microdissect single cells [16], fluo-
rescence-activated cell sorting (FACS) [17], and cDNA syn-
thesis from single cells [18,19]. A key issue for all these
techniques is that the isolated RNA needs to be faithfully
amplified. New approaches have made it possible to start
with a limited number of cells and still obtain sufficient
material for successful microarray experiments. For
example, Affymetrix has developed a double in vitro tran-
scription protocol that allows array hybridization to be based
on as little as 50 ng of total RNA from the starting material
[20]. These amplification methods will be particularly useful
for studies of the development of the nervous system, where
region-specific tissue amounts are very limited [13].
Recently, Yamagata and colleagues [21] have successfully
applied single-cell RT-PCR to retinal ganglion cells, in an
effort to identify those genes involved in regulating topo-
graphic mapping in the chick retinotectal projection. They
were able to identify Sidekick-1 and Sidekick-2, adhesion
molecules that appear to have a role in lamina-specific target
recognition. The applicability of this technology to microarray
studies remains to be explored, however.
Experimental replication and modes of data
analysis 
The analysis of data from microarrays is non-trivial. Many
problems may arise in developing a means for ranking
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Genome Biology 2003, 4:105genes, which is typically based on the degree of difference
between two experimental conditions. Regardless of the par-
ticular measure of differential expression that the researcher
settles on, it is now clear that methods based on replicate
independent arrays are necessary for accurate gene identifi-
cation (Figure 1). Even apart from variability in technique,
most neurobiological experiments face such inter-individual
and inter-group biological variability that it is unlikely that a
single array comparison will ever provide a reliable estimate
of gene-expression levels, even for pilot studies. As with any
other experiment, multiple independent trials are necessary
if we are to obtain accurate data.
The next challenge is to determine how many of the genes
estimated from the array expression data are truly regulated.
Hundreds, or thousands, of genes are examined in microarray
experiments. A single null hypothesis (for example, the
absence of regulation) is generally rejected when the proba-
bility of false rejection is 1/20. When hundreds of hypotheses
are tested in the same experiment, multiple significant test
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
http://genomebiology.com/2003/4/2/105                                                           Genome Biology 2003, Volume 4, Issue 2, Article 105 Griffin et al. 105.3
Genome Biology 2003, 4:105
Figure 1
Filtering array data. It is essential to remove as many false positives as possible at the earliest stages of analysis. Random errors occurring in
oligonucleotide array data were assessed by comparing three biologically independent control arrays to three other biologically independent control
arrays. Genes with a t test p < 0.05 in this comparison are plotted (a). Comparison of these results with the frequency of genes differing at p < 0.05
between control and experimental triplicate arrays (b) were used to define a set of criteria based on present/absent, fold change, t test p value, and a
signal threshold that minimized the estimated random error [31]. 
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Triplicate arrays Mean intensity plotsresults will be obtained. If each test was performed with a
threshold for a positive result of 0.05, then of the test results
identified as positives, it is likely that a subset of these will
be falsely assigned. Several different statistical corrections
are available to limit the accumulation of false positives,
most conservatively by dividing the p value threshold by the
number of hypothesis tests (Bonferroni correction). This
concern will be of the greatest importance when the popula-
tion under study contains rare true positives, as might occur
when comparing wild-type animals to mutants that have
very few transcriptional differences. Conversely, false posi-
tives will be less of a problem when there is a high prior
probability of true positives. Recently, methods have been
developed to limit the overall rate of falsely identified genes
with the specific case of microarray experiments in mind
[22]. This approach involves mathematically controlling the
overall proportion of false positives in the dataset, as
opposed to controlling the probability that any given test
result is a false positive. But the conservative nature of most
available statistical methods means that researchers often
find that even well-characterized genes with distinct differ-
ential expression patterns fall short of statistical signifi-
cance within array data sets. Thus, it might be appropriate
to consider the values of test statistics as a means for
weighting genes according to their reliability or promise for
further study, not as definitive rule-in or rule-out thresh-
olds. Researchers may also be able to define empirical sta-
tistical thresholds that are useful in their specific
experimental systems by performing appropriate control
experiments (Figure 1).
Microarray experiments offer the possibility of characterizing
the expression of large groups of genes simultaneously
using cluster analysis [23]. Briefly, clustering algorithms
may be divided into supervised and unsupervised
methods. Unsupervised methods are designed to group
similar expression patterns in a dataset without referring
to any outside information. The hierarchical, k-means, and
self-organizing map clustering algorithms fall into this cate-
gory, and they assist the researcher by identifying groups of
co-regulated genes. In contrast, supervised methods use
outside information about the experimental condition to
shape the derivation of a model from the dataset. For
example, a k-nearest neighbors algorithm was used by
Pomeroy  et al. [4] to derive a set of genes that predict
medulloblastoma treatment outcome. In addition to being
useful for the researcher in thinking about the large datasets
that result from microarray experiments and in shaping
future hypotheses, the groups of genes resulting from either
supervised or unsupervised clustering approaches can be
used as a platform for further studies of signaling systems or
metabolic pathways [24].
Grouping genes into functional categories on the basis of
data from other experimental systems [25] provides a useful
heuristic tool for analyzing microarray data. Websites have
been set up to assist functional categorization, notably the
KEGG database [26]. Grouping can be used either alone or
in combination with cluster analysis to identify genes of
related function that exhibit similar expression patterns over
time (Figure 2) [3]. But this type of analysis has potential
pitfalls when applied to the study of the nervous system:
genes identified in other systems in the body frequently have
entirely different functions in the nervous system. For
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Figure 2
Candidate gene identification. Schematic of a protocol that may be used
to select a few genes that obey a defined set of criteria. See text for
further details.
Data filtering
(see Figure 1) 
All genes
Group comparisons
Find common regulated genes across
multiple time courses  
Cluster analysis
Find common genes with desired regulatory patterns
Select genes on the basis of functional 
analysis, domain searches and other criteriaexample, the platelet-activating factor signaling system,
involved in platelet aggregation and blood clotting, and the
major histocompatibility (MHC) class I genes involved in
cell-mediated immunity, are both involved in developmental
patterning of the brain [27,28].
Experimental validation 
Once the appropriate mathematical tools have been used to
identify genes likely to be regulated in the manner of inter-
est, the next step is biological characterization of these
genes. The first stage of this process is validation, which
requires measuring the expression of specific genes of inter-
est using independent methods and independent RNA
samples. There are important reasons why a gene identified
on an array should be validated by another method. For
oligonucleotide arrays, the labeled RNA used for hybridiza-
tion to the chip is not the original RNA population but an
amplified copy whose production requires multiple enzy-
matic steps, each of which may bias array results. Cross-
hybridization due to sequence homology may lead to
erroneous results, especially when using cDNA arrays to
examine genes that have many closely related family
members. If all things were equal, then different probe sets
(or cDNAs) representing the same gene should behave iden-
tically on the same array, but this is often not the case [29].
To illustrate this problem, in a study of amygdala-enriched
genes, the authors were able to validate expression of only
approximately 60% of the transcripts identified by the
microarray analysis [14].
Several possibilities are available for confirming expression
patterns that are shared by multiple genes. Real-time PCR
allows the expression profiles of many genes to be plotted
across many RNA samples [30]. We have found that slot or
dot blotting of RNA is a successful alternative option:
placing RNA directly on a filter allows the use of relatively
low amounts of RNA per sample (1 µg of total RNA) and rea-
sonable scale production of filters (10-15 per hour) [31].
Visualizing changes in mRNA expression using in situ
hybridization allows the cellular localization of regulated
genes to be identified. This is critical for the nervous system,
where it is the specific pattern of circuitry that is the vital
information [14,32]. Finally, it should be stressed that inter-
pretations of microarray results rely only on mRNA
signals. Changes in intracellular distribution of proteins,
post-transcriptional modifications, receptor sensitization
and desensitization, protein dimerizations, and other
protein-protein interactions are beyond the scope of
microarray analysis. Substantial changes in protein levels
can occur in neurons without any detectable change in
mRNA, indicating that translation rate may be important in
determining the amounts of some proteins [33].
We are about to face a massive expansion of microarray
studies of the nervous system [34]. But realizing the full
potential of this technology requires a clear understanding of
the technical, bioinformatic and scientific issues. With atten-
tion to design, quality control and methods of analysis, the
potential rewards are great. 
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